BCMA CAR-NK (Shenzhen Pregene Biopharma) vs FT576

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

BCMA CAR-NK (Shenzhen Pregene Biopharma)

Developed by Shenzhen Pregene Biopharma Co., Ltd.

Phase 1/2 in Multiple Myelomaallogeneic CAR-NK cell therapy
Weak signal

NCT05652530 · Phase 1 · status unknown

This was an open-label, single-arm study with no randomization, no blinding, and no comparator arm, in only 19 participants, and it measured only safety. Results have not been posted yet.

No aligned efficacy figure on record for this race.

FT576

Developed by Fate Therapeutics

Phase 1 in Multiple Myelomacell therapy (allogeneic iPSC-derived CAR-NK)
Weak signal

NCT05182073 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Incidence and nature of DLTs within each dose-escalation cohort to determine the MTD or MAD (Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1); Determine the RP2D which will be based on the overall safety and anti-tumor activity among the dose escalation and dose expansion cohorts (From FPI to LPI's end of Cycle 1 study treatment (End of cycle is Day 29 from Day 1 FT576 infusion)); Incidence, nature, and severity of adverse events (Cycle 1 Day -5 to Day 29 for Regimen A and A1; Cycle 1 Day -11 to Day 29 (each cycle is 40 days) for Regimen B and B1): 12 patients were treated with a three-dose treatment schedule at 1 billion cells per dose (n=6) or 2.5 billion cells per dose (n=6). There were no dose-limiting toxicities and no events of any grade of CRS, ICANS or GvHD. Five of six (83%) heavily pre-treated patients achieved a clinical response at 1 billion cells per dose, including two penta-exposed patients treated with FT576 as monotherapy who achieved very good partial responses.

Result source: NCT05182073

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBCMA CAR-NK (Shenzhen Pregene Biopharma)FT576
PFS, median—Not reported—Not reported
OS, median—Not reported—Not reported
ORR—Not reported—Not reported
VGPR or better—Not reported—Not reported
MRD negativity—Not reported—Not reported

PFS, median

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
FT576
—Not reported

OS, median

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
FT576
—Not reported

ORR

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
FT576
—Not reported

VGPR or better

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
FT576
—Not reported

MRD negativity

BCMA CAR-NK (Shenzhen Pregene Biopharma)
—Not reported
FT576
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

BCMA CAR-NK (Shenzhen Pregene Biopharma): no structured comparison results are available for Multiple Myeloma.

FT576: no structured comparison results are available for Multiple Myeloma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCMA CAR-NK (Shenzhen Pregene Biopharma)'s landscape · FT576's landscape